.png){kind=icon}
.png){kind=icon}
Return
Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study
.png){kind=icon}
OA
AI
R
L
N
R
M
E
DOI：10.3390/curroncol33080449.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Cutaneous squamous cell carcinoma is among the most common skin cancers and is usually cured by surgical excision. A subset of tumors, however, becomes locally advanced or metastatic and requires multidisciplinary management. The introduction of immune checkpoint inhibitors targeting PD-1 has substantially changed the treatment of these advanced cases, but real-world data remain limited, particularly for patients excluded from registration trials. We analyzed 189 patients with advanced cutaneous squamous cell carcinoma treated at a Swiss tertiary referral centre between 2012 and 2022. From 2018 onwards, immunotherapy was rapidly adopted in both first- and second-line treatment, and survival improved in patients with metastatic disease. In contrast, organ transplant recipients and patients with chronic lymphocytic leukemia continued to show poor outcomes. As immunotherapy now moves into the neoadjuvant and adjuvant setting, these immunosuppressed populations remain underrepresented in trials and require dedicated prospective studies to guide their treatment.
Keywords:
cutaneous squamous cell carcinoma
anti-PD1
immunotherapy
real-world evidence
chronic lymphocytic leukemia
Journal
C
IF:
3.4
Papers:
780
Citations:
0
Organization
Cited Papers